Partnerships

Arecor and the Center for Process Innovation (CPI) Biologics are working on a project to enhance the compatibility of biologics with their containers.

NIH, 10 biopharmaceutical companies, and several nonprofit organizations form a partnership to develop new treatments earlier for Alzheimer's, type 2 diabetes, and autoimmune disorders.

Siemens enters agreement with Pfizer to commercialize diagnostic tests for therapeutic products across Pfizer's pipeline.

ProBioGen signs agreement with Emergent BioSolutions for access to ProBioGen's avian AGE1.CR cell line.

Octapharma and Pfizer form an agreement for the future marketing and commercialization of human prothrombin complex concentrate.

Additional companies join Merck KGaA and Neviah Genomics in the Israel BioIncubator.

Pure MHC and Catalent sign an agreement to develop RL21A using Catalent's GPEx technology.

A study to investigate metacomplex formation in the hetero-association of a multivalent antigen, streptavidin (SA), and a bivalent antibody (Ab) using a composition-gradient multiangle light-scattering (CG-MALS) system consisting of a composition-gradient device, a MALS detector, and a UV/Vis absorption detector.

Janssen Pharmaceuticals collaborates with CureVac and DCPrime in vaccines.

Advanced Biosciences Laboratories will support the development and production of a novel Shigella vaccine candidate for PATH.

J&J's Janssen and PATH partner to improve drug formulation that could help prevent HIV infection.

Are strategic partnerships in clinical research a model for CMC services?

ScinoPharm Changshu Pharmaceuticals and Sundia MediTech form an alliance for contract research and manufacturing services in mainland China.

Oncobiologics, Inc. and inVentiv Health announced a global strategic partnership around clinical development for all assets in Oncobiologic?s biosimilar pipeline.

The partnership provides access to Xencor’s Fc engineering patents for monoclonal antibodies.

Companies hope the collaboration will result in identifying potential new drug candidates using fewer rounds of design, synthesis, and testing.

The move is part of a strategy to cultivate innovation in key regions.

The multimillion deal focuses on oncology.

Agreement seeks to advance novel drug targets and focus on therapies for ulcerative colitis.

The agreement is worth up to $552 million, depending on meeting set milestones.

-

An innovative approach to capacity management.

The PATH Malaria Vaccine Initiative and Inovio Pharmaceuticals have announced a follow-on collaboration to advance the development of malaria vaccines and new vaccine delivery technologies.

GlaxoSmithKline has formed a partnership with Vodafone to use mobile technology to help vaccinate more children against common infectious diseases in Africa.

Working together affords many unseen opportunities for pharmaceutical innovation.